Type 2 diabetes and treatment intensification in primary care in Finland
To identify how the electronic health record (EHR) systems and national registers can be used for research purposes. We focused on how the primary care physicians adhere to clinical guidelines.
Study population included incident type 2 diabetes patients from four selected regions. Data were collected in two phases. At the first phase study cohort was identified using the prescription registers of the Social Insurance Institution (SII) and EHR systems used within the study regions. At second phase, data were collected from SII’s registers, local EHR systems, the hospital discharge and the primary care registers of National Institute for Health and Welfare.
Metformin was the most common choice as first drug. Among all study patients, 8375 (76.0%) started metformin monotherapy or combinations. The treatment was intensified at variable levels of HbA1c depending on the area. DPP4-inhibitors were by far the most common agent for treatment intensification. Sulphonylureas were used less often than basal insulin as the second-line agent. The use of DPP4-inhibitors increased between years 2009–2010, when first DPP4-inhibitor received reimbursement and this class became dominant drug for treatment intensification increasingly thereafter.
The EHR systems and national registers can be used for research purposes in Finland. The realization of diabetes treatment national guidelines are followed in primary care to a large extent. However, the subsequent intensification of therapy was delayed and occurred at elevated Hba1c levels.
KeywordsDiabetes Electronic health records Drug treatment Current care guidelines Type 2 diabetes
Compliance with ethical standards
Conflict of interest
The authors declare conflicts of interest regarding this manuscript as follows: Leo Niskanen—no conflicts of interest regarding this manuscript. Hahl, Jarmo -Epid Research Ltd, Payment for contributing. Leppä, Elli—No conflict of interest. Miettinen, Tatu—Epid Research Ltd, Payment for contributing. Mushnikov, Vasili—Pharma Industry Finland, Payment to Epid Research Ltd. Jari Haukka, Vasili Mushnikov, Pia Vattulainen and Pasi Korhonen work for EPID Research. EPID Research is a contract research organization and thus its employees have been and currently are working in collaboration with several pharmaceutical companies.
Human and Animal Rights
The whole study plan was approved by the Ethical Review Board of Helsinki University Hospital (HUS May 2013).
This is a register-based study with anonymous data and no patient contacts. Thus no consents from anonymized patients were required according to Finnish law.
- 6.Working group set up by the Finnish Medical Society Duodecim and the Finnish Society of Internal Medicine and the Medical Advisory Board of the Finnish Diabetes Society. Diabetes. Current Care Guidelines http://www.kaypahoito.fi/web/english/guidelineabstracts/guideline. Assessed 2016
- 8.Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379CrossRefGoogle Scholar
- 9.Ngsp.org. (2018) NGSP. IFCC Standardization Overview. http://www.ngsp.org/ifcc.asp. Accessed 18 June 2018
- 10.Encepp.eu. (2018). ER12-9451 Realization of the clinical practice guidelines for diabetes in Finland—a case study of the usability of electronic patient information systems and national registers to support evidence based decision making in health care. http://www.encepp.eu/encepp/viewResource.htm?id=14809. Accessed 18 June 2018
- 11.Nomesko (2017) Health Statistics for the Nordic Countries 2017, 1st edn. NOMESCO-NOSOSCO, Copenhagen, p 238. http://urn.kb.se/resolve?urn=urn:nbn:se:norden:org:diva-4982. Accessed 20 Feb 2018